Therefore, it was suggested that monitoring Gal-3 in addition to hs-TnT and NT-proBNP may be a more complete assessment for cardiovascular event risk in COPD patients [76]. The gene discussed is LGALS3; the disease is chronic obstructive pulmonary disease.